39,591 results on '"Albuminuria"'
Search Results
2. Efficacy and Safety of Lorundrostat Alone, and in Combination With Dapagliflozin in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
- Published
- 2024
3. Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia (PLUTO)
- Author
-
Juvenile Diabetes Research Foundation, King's College London, and Glostrup University Hospital, Copenhagen
- Published
- 2024
4. Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin. (@HOME)
- Author
-
AstraZeneca
- Published
- 2024
5. Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial (Optimize@Home)
- Author
-
Boehringer Ingelheim
- Published
- 2024
6. TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension (TIMOTHY)
- Author
-
AstraZeneca
- Published
- 2024
7. Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria
- Author
-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Aminu Kano Teaching Hospital, SAIC-Frederick, Inc., Brigham and Women's Hospital, and C. William Wester, Professor of Medicine
- Published
- 2024
8. GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes (1981)
- Author
-
AstraZeneca and Paresh Dandona, SUNY Distinguished Professor
- Published
- 2024
9. PrevaLence of Albuminuria in Patients With CARdiovascular Disease and Type 2 Diabetes Mellitus in China: a National Cross-sectional Study (PLACARD)
- Author
-
Chang sheng Ma, Director of Cardiology
- Published
- 2024
10. Plasma proenkephalin A and incident chronic kidney disease and albuminuria in the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort.
- Author
-
Bullen, Alexander, Katz, Ronit, Poursadrolah, Sayna, Short, Samuel, Long, D, Cheung, Katharine, Sharma, Shilpa, Al-Rousan, Tala, Fregoso, Alma, Schulte, Janin, Gutierrez, Orlando, Shlipak, Michael, Cushman, Mary, Ix, Joachim, and Rifkin, Dena
- Subjects
albuminuria ,biomarker ,chronic kidney disease ,proenkephalin A ,Humans ,Female ,Middle Aged ,Male ,Albuminuria ,Race Factors ,Renal Insufficiency ,Chronic ,Stroke ,Enkephalins ,Protein Precursors - Abstract
BACKGROUND: Plasma proenkephalin A (PENK-A) is a precursor of active enkephalins. Higher blood concentrations have been associated with estimated glomerular filtration rate (eGFR) decline in European populations. Due to the significant disparity in incident chronic kidney disease (CKD) between White and Black people, we evaluated the association of PENK-A with incident CKD and other kidney outcomes among a biracial cohort in the U.S. METHODS: In a nested cohort of 4,400 participants among the REasons for Geographic And Racial Differences in Stroke, we determined the association between baseline PENK-A concentration and incident CKD using the creatinine-cystatin C CKD-EPI 2021 equation without race coefficient, significant eGFR decline, and incident albuminuria between baseline and a follow-up visit 9.4 years later. We tested for race and sex interactions. We used inverse probability sampling weights to account for the sampling design. RESULTS: At baseline, mean (SD) age was 64 (8) years, 49% were women, and 52% were Black participants. 8.5% developed CKD, 21% experienced ≥ 30% decline in eGFR and 18% developed albuminuria. There was no association between PENK-A and incident CKD and no difference by race or sex. However, higher PENK-A was associated with increased odds of progressive eGFR decline (OR: 1.12; 95% CI 1.00, 1.25). Higher PENK-A concentration was strongly associated with incident albuminuria among patients without diabetes mellitus (OR: 1.29; 95% CI 1.09, 1.53). CONCLUSION: While PENK-A was not associated with incident CKD, its associations with progression of CKD and incident albuminuria, among patients without diabetes, suggest that it might be a useful tool in the evaluation of kidney disease among White and Black patients.
- Published
- 2024
11. Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
- Published
- 2024
12. Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors (PRIMETIME2)
- Author
-
Rigshospitalet, Denmark, Hillerod Hospital, Denmark, Zealand University Hospital, Holbaek Sygehus, Slagelse Sygehus, Nykøbing Falster County Hospital, Aarhus University Hospital, The Novo Nordisk Foundation Center for Basic Metabolic Research, Novo Nordisk A/S, Gubra ApS, Odense University Hospital, Aalborg University Hospital, Gødstrup Hospital, Steno Diabetes Center Copenhagen, Steno Diabetes Center Sjaelland, Steno Diabetes Center Nordjylland, Michigan Kidney Translational Medical Center, and Marie Møller, MD, PhD-student
- Published
- 2024
13. Screening for Albuminuria at the First Line for Early Identification of CKD (SALINE)
- Author
-
University Medical Center Groningen
- Published
- 2024
14. KidneYou - Innovative Digital Therapy
- Published
- 2024
15. Lessons learned from the FinnDiane Study: Epidemiology and metabolic risk factors for diabetic kidney disease in type 1 diabetes.
- Author
-
Jansson Sigfrids, Fanny, Lithovius, Raija, Groop, Per‐Henrik, and Thorn, Lena M.
- Subjects
- *
TYPE 1 diabetes , *METABOLIC syndrome , *KIDNEY failure , *INSULIN resistance , *ADIPOSE tissues , *DIABETIC nephropathies - Abstract
Aims Methods Results Conclusion Across its operational span of more than 25 years, the observational, nationwide, multicentre Finnish Diabetic Nephropathy (FinnDiane) Study has aimed to unravel mechanisms underlying diabetic kidney disease, with a special focus on its metabolic risk factors. We sought to compile key findings relating to this topic and to offer a current perspective on the natural course of diabetic kidney disease among individuals with type 1 diabetes.In this narrative review, articles relevant to the subject published by the FinnDiane Study were identified and summarized together with work published by others, when relevant.The FinnDiane Study has underscored the significance of dysglycaemia and insulin resistance, increased visceral fat mass, hypertension and dyslipidaemia—particularly high triglycerides and remnant cholesterol—as risk factors for diabetic kidney disease. Factors like abdominal obesity seem to influence the early stages of the disease, while the presence of the metabolic syndrome becomes implicated at later stages. Epidemiological reports have revealed that after an initial decline, the cumulative incidence of albuminuria plateaued post‐1980s, with the progression rate to kidney failure remaining high. Fortunately, 23% of the FinnDiane cohort regressed to less advanced stages of albuminuria, improving their overall prognosis.A substantial burden of albuminuria associated with type 1 diabetes persists, and therefore, novel kidney‐protecting therapies are highly awaited. In addition, given that metabolic factors influence the progression of diabetic kidney disease both in its early and advanced stages, emphasis should be placed on ensuring that their treatment targets are met. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Dyslipidemia in children with chronic kidney disease—findings from the Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) study.
- Author
-
Mencarelli, Francesca, Azukaitis, Karolis, Kirchner, Marietta, Bayazit, Aysun, Duzova, Ali, Canpolat, Nur, Bulut, Ipek Kaplan, Obrycki, Lukasz, Ranchin, Bruno, Shroff, Rukshana, Caliskan, Salim, Candan, Cengiz, Yilmaz, Alev, Özcakar, Zeynep Birsin, Halpay, Harika, Kiyak, Aysel, Erdogan, Hakan, Gellermann, Jutta, Balat, Ayse, and Melk, Anette
- Subjects
- *
CROSS-sectional method , *PROTEINURIA , *PREPROCEDURAL fasting , *HYPERLIPIDEMIA , *RESEARCH funding , *SECONDARY analysis , *CREATININE , *DISEASE duration , *BODY mass index , *LIPIDS , *DESCRIPTIVE statistics , *AGE distribution , *DIASTOLIC blood pressure , *ALBUMINS , *TRIGLYCERIDES , *REGRESSION analysis , *GLOMERULAR filtration rate , *SERUM albumin , *DISEASE risk factors , *CHILDREN ,CHRONIC kidney failure complications - Abstract
Background: Dyslipidemia is an important and modifiable risk factor for CVD in children with CKD. Methods: In a cross-sectional study of baseline serum lipid levels in a large prospective cohort study of children with stage 3–5 (predialysis) CKD, frequencies of abnormal lipid levels and types of dyslipidemia were analyzed in the entire cohort and in subpopulations defined by fasting status or by the presence of nephrotic range proteinuria. Associated clinical and laboratory characteristics were determined by multivariable linear regression analysis. Results: A total of 681 patients aged 12.2 ± 3.3 years with a mean eGFR of 26.9 ± 11.6 ml/min/1.73 m2 were included. Kidney diagnosis was classified as CAKUT in 69%, glomerulopathy in 8.4%, and other disorders in 22.6% of patients. Nephrotic range proteinuria (defined by a urinary albumin/creatinine ratio > 1.1 g/g) was present in 26.9%. Dyslipidemia was found in 71.8%, and high triglyceride (TG) levels were the most common abnormality (54.7%). Fasting status (38.9%) had no effect on dyslipidemia status. Except for a significant increase in TG in more advanced CKD, lipid levels and frequencies of dyslipidemia were not significantly different between CKD stages. Hypertriglyceridemia was associated with younger age, lower eGFR, shorter duration of CKD, higher body mass index (BMI-SDS), lower serum albumin, and higher diastolic blood pressure. Conclusions: Dyslipidemia involving all lipid fractions, but mainly TG, is present in the majority of patients with CKD irrespective of CKD stage or fasting status and is significantly associated with other cardiovascular risk factors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Associations of Kidney Tubular Biomarkers With Incident Macroalbuminuria and Sustained Low eGFR in DCCT/EDIC.
- Author
-
Limonte, Christine P., Gao, Xiaoyu, Bebu, Ionut, Seegmiller, Jesse C., Karger, Amy B., Lorenzi, Gayle M., Molitch, Mark, Karanchi, Harsha, Perkins, Bruce A., and de Boer, Ian H.
- Subjects
- *
DIABETIC nephropathies , *TYPE 1 diabetes , *DIABETES complications , *GLOMERULAR filtration rate , *ALBUMINURIA - Abstract
OBJECTIVE: Tubulointerstitial injury contributes to diabetic kidney disease (DKD) progression. We tested tubular biomarker associations with DKD development in type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: We performed a case-cohort study examining associations of tubular biomarkers, measured across seven time points spanning ∼30 years, with incident macroalbuminuria ("severely elevated albuminuria," urinary albumin excretion rate [AER] ≥300 mg/day) and sustained low estimated glomerular filtration rate (eGFR) (persistent eGFR <60 mL/min/1.73 m2) in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) study. Biomarkers included KIM-1 and sTNFR1 in serum/plasma, MCP-1 and EGF in urine, and a composite tubular secretion score reflecting secreted solute clearance. We assessed biomarkers using single values, as mean values from consecutive time points, and as change over consecutive time points, each as time-updated exposures. RESULTS: At baseline, mean diabetes duration was 5.9 years, with mean HbA1c 8.9%, eGFR 125 mL/min/1.73 m2, and AER 16 mg/day. There were 4.8 and 3.5 cases per 1,000 person-years of macroalbuminuria and low eGFR, respectively. Assessed according to single biomarker values, KIM-1 was associated with risk of subsequent macroalbuminuria and low eGFR (hazard ratio [HR] per 20% higher biomarker 1.11 [95% CI 1.06, 1.16] and 1.12 [1.04, 1.21], respectively) and sTNFR1 was associated with subsequent macroalbuminuria (1.14 [1.03, 1.25]). Mean KIM-1 and EGF–to–MCP-1 ratio were associated with subsequent low eGFR. In slope analyses, increases in KIM-1 and sTNFR1 were associated with subsequent macroalbuminuria (per 20% biomarker increase, HR 1.81 [1.40, 2.34] and 1.95 [1.18, 3.21]) and low eGFR (2.26 [1.65, 3.09] and 2.94 [1.39, 6.23]). CONCLUSIONS: Serial KIM-1 and sTNFR1 are associated with incident macroalbuminuria and sustained low eGFR in T1D. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy.
- Author
-
Nagasawa, Hajime, Ueda, Seiji, Suzuki, Hitoshi, Jenkinson, Celia, Fukao, Yusuke, Nakayama, Maiko, Otsuka, Tomoyuki, Okuma, Teruyuki, Clapper, Wilmelenne, Liu, Kai, Nguyen, Mai, Komers, Radko, and Suzuki, Yusuke
- Subjects
- *
ENDOTHELIN receptors , *CLINICAL trials , *ANGIOTENSIN II , *IGA glomerulonephritis , *ANGIOTENSIN receptors - Abstract
Background The mechanism leading to the development of immunoglobulin A nephropathy (IgAN) remains to be completely understood. Endothelin-1 (ET-1) as well as angiotensin II (AngII) promote glomerular injury, tubulointerstitial inflammation and fibrosis leading to chronic kidney disease. Sparsentan, a dual endothelin angiotensin receptor antagonist, recently received accelerated approval in the USA for the reduction of proteinuria in adults with IgAN at high risk of disease progression. To elucidate the mechanisms by which sparsentan is efficacious in IgAN, we examined the effect of treatment in gddY mice, a spontaneous IgAN mouse model, versus the monoselective angiotensin II type 1 receptor (AT1R) antagonist, losartan, on the development of renal injury at doses resulting in similar blood pressure lowering. Methods Four-week-old gddY mice were given control chow, chow containing sparsentan or drinking water containing losartan until 12 or 20 weeks old. Results Remarkably, the albumin:creatine ratio (ACR) was attenuated more rapidly and to a greater extent in mice treated with sparsentan than those treated with losartan. The decrease in ACR from baseline after 4 weeks of treatment correlated with beneficial effects of sparsentan on glomerulosclerosis and protection of podocytes and glycocalyx after 16 weeks of treatment across treatment groups; thus, sparsentan treatment delayed development of renal injury to a greater extent than losartan. Expression of mRNA for ET-1, endothelin type A receptor and AT1R and proinflammatory genes was upregulated in 12-week-old gddY mice and was prevented by sparsentan and losartan to a comparable extent. Conclusions The results of this study, and in light of the results of the phase 3 PROTECT trial, provide a novel perspective and understanding of the mechanisms by which sparsentan has a beneficial renoprotective effect against IgAN compared with AT1R antagonism alone. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. The relationship between hypomagnesemia and albuminuria in patients with type 2 diabetes mellitus.
- Author
-
Eker, Edibe S. and Ataoğlu, Hayriye E.
- Subjects
- *
TYPE 2 diabetes , *DIABETIC nephropathies , *LOGISTIC regression analysis , *CHRONIC kidney failure , *HYPOMAGNESEMIA - Abstract
Objective: Diabetic nephropathy is a prevalent cause of chronic kidney disease worldwide. Magnesium plays a critical role in insulin resistance, and insulin, in turn, regulates magnesium levels. We aimed to investigate the association between hypomagnesemia and albuminuria in patients with type 2 diabetes mellitus (T2DM). Design, Patients and Measurements: This retrospective single‐centre study encompassed 1178 patients aged 18 and above with T2DM, who attended our outpatient clinic between January 2019 and August 2020. Albuminuria levels were categorised according to Kidney Disease Outcomes Quality Initiative guidelines. In the literature, when examining cut‐off values for hypomagnesemia, it is observed that studies typically use hospital normal level as a reference point. Hypomagnesemia, defined as magnesium levels below 1.6 mg/dL, was compared to normomagnesemia (magnesium between 1.6 and 2.4 mg/dL). The primary objective was to explore the impact of magnesium levels on albuminuria, while the secondary objective was to determine the prevalence of hypomagnesemia. The multivariate logistic regression analyses were performed according to age, gender (male), HbA1c, and presence of hypomagnesemia. Results: The mean age of the participants was 58.7 ± 12.2 years, with 44% being male. Hypomagnesemia was identified in 5.3% of the patients. Advanced age and female gender were more common among patients with hypomagnesemia (p =.001). Magnesium levels exhibited a negative correlation with HbA1c and fasting blood glucose, and a positive correlation with creatinine levels (r = −.117, r = −.131, r =.117, p <.001 for all three variables). Hypomagnesemia was significantly more prevalent in patients with albuminuria (15.9% vs. 4.7%, p <.001). Moreover, participants with the presence of hypomagnesemia were independently associated with a higher risk of albuminuria (odds ratio 3,64 1.76–7.52, p =.001). Conclusion: Albuminuria is more frequently observed in patients with hypomagnesemia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Guidelines for clinical evaluation of chronic kidney disease in early stages: AMED research on regulatory science of pharmaceuticals and medical devices.
- Author
-
Sugawara, Yuka, Kanda, Eiichiro, Hamano, Takayuki, Itano, Seiji, Okada, Hirokazu, Tomori, Koji, Watanabe, Yusuke, Asakura, Wataru, Isaka, Yoshitaka, Iseki, Kunitoshi, Usui, Tomoko, Suzuki, Yusuke, Tanaka, Mototsugu, Nishimura, Rimei, Fukami, Kei, Matsushita, Kunihiro, Wada, Jun, Watada, Hirotaka, Ueki, Kohjiro, and Kashihara, Naoki
- Subjects
- *
DIABETIC nephropathies , *MEDICAL sciences , *CHRONIC kidney failure , *DISEASE risk factors , *ALBUMINURIA - Abstract
Background: For the development of pharmaceutical products in kidney field, appropriate surrogate endpoints which can predict long-term prognosis are needed as an alternative to hard endpoints, such as end-stage kidney disease. Though international workshop has proposed estimated glomerular filtration rate (GFR) slope reduction of 0.5–1.0 mL/min/1.73 m /year and 30% decrease in albuminuria/proteinuria as surrogate endpoints in early and advanced chronic kidney disease (CKD), it was not clear whether these are applicable to Japanese patients. Methods: We analyzed J-CKD-DB and CKD-JAC, Japanese databases/cohorts of CKD patients, and J-DREAMS, a Japanese database of patients with diabetes mellitus to investigate the applicability of eGFR slope and albuminuria/proteinuria to the Japanese population. Systematic review on those endpoints was also conducted including the results of clinical trials published after the above proposal. Results: Our analysis showed an association between eGFR slope and the risk of end-stage kidney disease. A 30% decrease in albuminuria/proteinuria over 2 years corresponded to a 20% decrease in the risk of end-stage kidney disease patients with baseline UACR ≥ 30 mg/gCre or UPCR ≥ 0.15 g/gCre in the analysis of CKD-JAC, though this analysis was not performed on the other database/cohort. Those results suggested similar trends to those of the systematic review. Conclusion: The results suggested that eGFR slope and decreased albuminuria/proteinuria may be used as a surrogate endpoint in clinical trials for early CKD (including diabetic kidney disease) in Japanese population, though its validity and cutoff values must be carefully considered based on the latest evidence and other factors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Niereninsuffizienz und onkologische Erkrankungen – eine Wechselbeziehung.
- Author
-
Dikow, Ralf and Zeier, Martin
- Abstract
Copyright of Die Nephrologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
22. Correlation of serum thyrotropin and thyroid hormone levels with diabetic kidney disease: a cross-sectional study.
- Author
-
Gao, Jie and Liu, Jingfang
- Subjects
- *
DIABETES complications , *CROSS-sectional method , *THYROXINE , *PREDICTIVE tests , *ALBUMINURIA , *RECEIVER operating characteristic curves , *BODY mass index , *GLYCOSYLATED hemoglobin , *RESEARCH funding , *DIABETIC nephropathies , *LOGISTIC regression analysis , *SEX distribution , *DESCRIPTIVE statistics , *AGE distribution , *THYROID hormones , *ODDS ratio , *CHOLESTEROL , *THYROTROPIN , *CONFIDENCE intervals , *ALBUMINS , *BIOMARKERS , *GLOMERULAR filtration rate , *HYPOTHYROIDISM , *C-reactive protein - Abstract
Objective: The relationship between thyrotropin (TSH), free triiodothyronine (FT3), free thyroxine (FT4) and diabetic kidney disease (DKD) is still controversial, and this study analyzed the correlation between TSH, FT3, FT4 and DKD in patients with type 2 diabetes mellitus (T2DM). Methods: T2DM patients (1216) were divided into five groups based on serum TSH, FT3, and FT4 levels, differences in urinary albumin excretion rate (UACR), estimated glomerular filtration rate (eGFR) were compared. Binary logistic regression verified independent correlations among TSH, FT3, FT4 and UACR, eGFR. TSH and FT3 predictive values for DKD were analyzed using receiver operating characteristic (ROC) curves. Results: The prevalence of albuminuria with decreased eGFR was higher in T2DM patients with subclinical hypothyroidism and overt hypothyroidism than that in patients with normal thyroid function. TSH positively correlated with UACR (r = 0.133, p < 0.001) and positively correlated with eGFR (r = -0.218, p < 0.001), FT3 negatively correlated with UACR (r = -0.260, p < 0.001) and positively correlated with eGFR (r = 0.324, p < 0.001). With the change from the lower normal level to the increased level of TSH and the change from the higher normal level to the reduced level of FT3, the prevalence of albuminuria gradually increased, the prevalence of decreased eGFR gradually increased in TSH groups and FT3 groups. After adjusting for age, BMI, duration of diabetes, TPOAb, TGAb, smoking, drinking, hypertension, the use of anti-diabetic medications (metformin, sodium–glucose cotransporter 2 inhibitors), HbA1c, CRP, TC, TG, LDL-C, and HDL-C, both TSH and FT3 correlated with increased UACR (TSH: OR 1.253, p = 0.001; FT3: OR 0.166, p < 0.001) and decreased eGFR (TSH: OR 1.245, p < 0.001, FT3: OR 0.579, p < 0.001), but this correlation of TSH with eGFR < 60 mL/min/1.73 m2 was not found in male. The area under the ROC curve (AUC) for FT3 was greater than that for TSH (FT3: 0.64; TSH: 0.61). Conclusions: Increased TSH and reduced FT3 levels were associated with DKD in T2DM patients, but in a sex-dependent manner. FT3 had a higher predictive value for DKD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Epicardial and liver fat implications in albuminuria: a retrospective study.
- Author
-
Perdomo, Carolina M., Martin-Calvo, Nerea, Ezponda, Ana, Mendoza, Francisco J., Bastarrika, Gorka, Garcia-Fernandez, Nuria, Herrero, José I., Colina, Inmaculada, Escalada, Javier, and Frühbeck, Gema
- Subjects
- *
EPICARDIAL adipose tissue , *ADIPOSE tissue diseases , *CHRONIC kidney failure , *CARDIOVASCULAR diseases , *TYPE 2 diabetes - Abstract
Background: Albuminuria is considered an early and sensitive marker of kidney dysfunction, but also an independent cardiovascular risk factor. Considering the possible relationship among metabolic liver disease, cardiovascular disease and chronic kidney disease, we aimed to evaluate the risk of developing albuminuria regarding the presence of epicardial adipose tissue and the steatotic liver disease status. Methods: A retrospective long-term longitudinal study including 181 patients was carried out. Epicardial adipose tissue and steatotic liver disease were assessed by computed tomography. The presence of albuminuria at follow-up was defined as the outcome. Results: After a median follow up of 11.2 years, steatotic liver disease (HR 3.15; 95% CI, 1.20–8.26; p = 0.02) and excess amount of epicardial adipose tissue (HR 6.12; 95% CI, 1.69–22.19; p = 0.006) were associated with an increased risk of albuminuria after adjustment for visceral adipose tissue, sex, age, weight status, type 2 diabetes, prediabetes, hypertriglyceridemia, hypercholesterolemia, arterial hypertension, and cardiovascular prevention treatment at baseline. The presence of both conditions was associated with a higher risk of developing albuminuria compared to having steatotic liver disease alone (HR 5.91; 95% CI 1.15–30.41, p = 0.033). Compared with the first tertile of visceral adipose tissue, the proportion of subjects with liver steatosis and abnormal epicardial adipose tissue was significantly higher in the second and third tertile. We found a significant correlation between epicardial fat and steatotic liver disease (rho = 0.43 [p < 0.001]). Conclusions: Identification and management/decrease of excess adiposity must be a target in the primary and secondary prevention of chronic kidney disease development and progression. Visceral adiposity assessment may be an adequate target in the daily clinical setting. Moreover, epicardial adipose tissue and steatotic liver disease assessment may aid in the primary prevention of renal dysfunction. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. A new perspective on proteinuria and drug therapy for diabetic kidney disease.
- Author
-
Ruimin Zhang, Qian Wang, Yaqing Li, Qihu Li, Xuefeng Zhou, Xiangmei Chen, and Zheyi Dong
- Subjects
DIABETIC nephropathies ,CHRONIC kidney failure ,MINERALOCORTICOID receptors ,ALBUMINURIA ,CARDIOVASCULAR diseases ,ENDOTHELIN receptors - Abstract
Diabetic kidney disease (DKD) is one of the leading causes of end-stage renal disease worldwide and significantly increases the risk of premature death due to cardiovascular diseases. Elevated urinary albumin levels are an important clinical feature of DKD. Effective control of albuminuria not only delays glomerular filtration rate decline but also markedly reduces cardiovascular disease risk and all-cause mortality. New drugs for treating DKD proteinuria, including sodium-glucose cotransporter two inhibitors, mineralocorticoid receptor antagonists, and endothelin receptor antagonists, have shown significant efficacy. Auxiliary treatment with proprietary Chinese medicine has also yielded promising results; however, it also faces a broader scope for development. The mechanisms by which these drugs treat albuminuria in patients with DKD should be described more thoroughly. The positive effects of combination therapy with two or more drugs in reducing albuminuria and protecting the kidneys warrant further investigation. Therefore, this review explores the pathophysiological mechanism of albuminuria in patients with DKD, the value of clinical diagnosis and prognosis, new progress and mechanisms of treatment, and multidrug therapy in patients who have type 2 diabetic kidney disease, providing a new perspective on the clinical diagnosis and treatment of DKD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Association of Epicardial Adiposity and Albuminuria in Patient with Essential Hypertension.
- Author
-
Mohan, Gurinder and Khanna, Kapeesh
- Abstract
Aim: The aim of the present study was to find an association of epicardial adiposity and albuminuria patients with essential hypertension. Methods: The Observational study was conducted in the Department of Medicine, SGRDIMSR, Vallah, Sri Amritsar from April 2021 to July 2022. In this study, 100 patients aged 18-60 years having essential hypertension were enrolled. Patients were divided into 2 groups depending upon UACR i.e albuminuria(>30mg/dl) and albuminuria(<30mg/dl) coming to medicine opd or getting admitted in SGRDIMSR fulfilling the inclusion criteria after giving written and informed consent. Results: Out of 100 patients, majority of the patients (64%) belonged to 51-60 age group followed by 41-50 years (15%), 31-40 years (13%), and 21-30 years (8%) age group. Mean age of the patients was 49.96±11.35 years. 51% were males and 49% were females. 46% of patients had BMI 23-24.9 followed by >25 (32%), 18.5-22.9 (19%), and <18.5 (3%). Mean BMI of the patients was 24.54±3.27. Stage I hypertension was present in 66% of the patients, while stage II was present in 34% of patients. Left Ventricular Hypertrophy (LVH) was present in 84% of patients and absent in 16% of patients. 78% patients had serum albumin levels 3.5- 5.5 mg/dl and 22% patients had serum albumin levels <3.5 mg/dl. Mean albumin levels were 4.0130±0.54747 mg/dl. Conclusion: From this study it can be concluded that epicardial adipose tissue thickness and albuminuria was significantly associated with Hypertension. The relation of UACR levels with left ventricular hypertrophy and LVMI was found statistically significant. Similarly, the relation of epicardial adipose tissue thickness and serum albumin levels were significantly associated. [ABSTRACT FROM AUTHOR]
- Published
- 2024
26. Long-term outcomes of patients with IgA nephropathy in the German CKD cohort.
- Author
-
Stamellou, Eleni, Nadal, Jennifer, Hendry, Bruce, Mercer, Alex, Seikrit, Claudia, Bechtel-Walz, Wibke, Schmid, Matthias, Moeller, Marcus J, Schiffer, Mario, Eckardt, Kai-Uwe, Kramann, Rafael, Floege, Jürgen, and investigators, the GCKD study
- Subjects
- *
MAJOR adverse cardiovascular events , *RENAL replacement therapy , *PROPORTIONAL hazards models , *IGA glomerulonephritis , *CHRONIC kidney failure - Abstract
Background The importance of albuminuria as opposed to proteinuria in predicting kidney outcomes in primary immunoglobulin A nephropathy (IgAN) is not well established. Methods From 2010 to 2012, 421 patients with biopsy-proven IgAN have been enrolled into the German Chronic Kidney Disease (GCKD) cohort, a prospective observational cohort study (N = 5217). Adjudicated endpoints include a composite kidney endpoint (CKE) consisting of eGFR decline >40%, eGFR <15 ml/min/1.73 m2 and initiation of kidney replacement therapy; the individual components of the CKE; and combined major adverse cardiac events (MACE), including non-fatal myocardial infarction, non-fatal stroke and all-cause mortality. The associations between the incidence of CKE and baseline factors, including demographics, laboratory values and comorbidities were analysed using the Cox proportional hazards regression model. Results The mean age of IgAN patients at baseline was 51.6 years (± 13.6) and 67% were male. The patient-reported duration of disease at baseline was 5.9 ± 8.1 years. Baseline median urine albumin:creatinine ratio (UACR) was 0.4 g/g [interquartile range (IQR) 0.1–0.8] and mean eGFR was 52.5 ± 22.4 ml/min/1.73 m2. Over a follow-up of 6.5 years, 64 (15.2%) patients experienced a >40% eGFR decline, 3 (0.7%) reached eGFR <15 ml/min/1.73 m2, 53 (12.6%) initiated kidney replacement therapy and 28% of the patients experienced the CKE. Albuminuria, with reference to <0.1 g/g, was most associated with CKE. Hazard ratios (HRs) at UACRs of 0.1–0.6 g/g, 0.6–1.4 g/g, 1.4–2.2 g/g and >2.2 g/g were 2.03 [95% confidence interval (CI) 1.02–4.05], 3.8 (95% CI 1.92–7.5), 5.64 (95% CI 2.58–12.33) and 5.02 (95% CI 2.29–11-03), respectively. Regarding MACE, the presence of diabetes [HR 2.53 (95% CI 1.11–5.78)] was the most strongly associated factor, whereas UACR and eGFR did not show significant associations. Conclusion In the GCKD IgAN subcohort, more than every fourth patient experienced a CKE event within 6.5 years. Our findings support the use of albuminuria as a surrogate to assess the risk of poor kidney outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Impact of Dapagliflozin Adjunctive Therapy on the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 2-5: A systematic review and meta-analysis.
- Author
-
M., Kanimozhi, Bisht, Manisha, Morang, Sikha, Thapliyal, Surabhi, Bassan, Manbir S., and Handu, Shailendra
- Subjects
- *
CHRONIC kidney failure , *TYPE 2 diabetes , *CHRONICALLY ill , *DAPAGLIFLOZIN , *DISEASE progression - Abstract
This meta-analysis investigated efficacy of dapagliflozin as adjunctive therapy for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) stages 2-5. A systematic search was conducted of selected databases for randomised controlled trials that reported the mean change in estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (UACR) from baseline. Out of 1,682 identified studies, 9 trials comprising 13,057 patients were included. A pooled estimate of 5 studies indicated that dapagliflozin did not affect eGFR; however, in 2 studies, it significantly reduced chronic eGFR decline compared to placebo (mean difference [MD] ± 2.74; 95% confidence interval [CI]: 1.55, 3.92; P <0.00001). Additionally, a pooled estimate of 4 studies showed that dapagliflozin significantly reduced UACR (MD -23.99%; 95% CI: -34.82--13.15; P <0.0001; I2 = 0%). Therefore, long-term use of dapagliflozin significantly attenuates eGFR decline and reduces albuminuria in patients with T2DM and CKD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Dihydropyridine Calcium Channel Blockers and Kidney Outcomes.
- Author
-
Blum, Matthew F., Surapaneni, Aditya, Chang, Alexander, Inker, Lesley A., Chen, Teresa K., Appel, Lawrence J., Shin, Jung-Im, and Grams, Morgan E.
- Subjects
- *
CALCIUM antagonists , *DIABETIC nephropathies , *DIHYDROPYRIDINE , *SYSTOLIC blood pressure , *ELECTRONIC health records , *ALBUMINURIA - Abstract
Background: Early trials of dihydropyridine calcium channel blockers (DCCBs) suggest a detrimental effect on intraglomerular pressure and an association with albuminuria. Objective: We sought to evaluate the associations of DCCB initiation with albuminuria and kidney failure with replacement therapy (KFRT) and to determine whether renin-angiotensin system (RAS) blockade modified these associations. Design: We conducted a target trial emulation study using a new user, active comparator design and electronic health record data from Geisinger Health. Participants: We included patients without severe albuminuria or KFRT who were initiated on a DCCB or thiazide (active comparator) between January 1, 2004, and December 31, 2019. Main Measures: Using inverse probability of treatment weighting, we performed doubly robust Cox proportional hazards regression to estimate the association of DCCB initiation with incident severe albuminuria (urine albumin to creatinine ratio > 300 mg/g) and KFRT, overall and stratified by RAS blocker use. Key Results: There were 11,747 and 26,758 eligible patients initiating a DCCB and thiazide, respectively, with a weighted baseline mean age of 60 years, systolic blood pressure of 143 mm Hg, and eGFR of 86 mL/min/1.73 m2, and with a mean follow-up of 8 years. Compared with thiazides, DCCBs were significantly associated with the development of severe albuminuria (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.16–1.43), with attenuation of risk in the presence of RAS blockade (P for interaction < 0.001). The risk of KFRT was increased among patients without RAS blockade (HR, 1.66; 95% CI, 1.19–2.31), but not with RAS blockade (P for interaction = 0.005). Conclusions: DCCBs were associated with increased risk of albuminuria and, in the absence of RAS blockade, KFRT. These findings suggest coupling DCCB therapy with RAS blockade may mitigate adverse kidney outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria.
- Author
-
Nakhleh, Afif, Abdul‐Ghani, Muhammad, Gazit, Sivan, Gross, Adi, Livnat, Idit, Greenbloom, Maya, Yarden, Adva, Khazim, Khaled, Shehadeh, Naim, and Melzer Cohen, Cheli
- Subjects
- *
CHRONIC kidney failure , *CHRONICALLY ill , *HEALTH maintenance organizations , *SODIUM-glucose cotransporter 2 inhibitors , *ALBUMINURIA - Abstract
Aim: To examine the renal effects of sodium‐glucose cotransporter‐2 (SGLT2) inhibition among non‐diabetic individuals with chronic kidney disease (CKD) in a real‐world setting. Methods: We collected de‐identified data on adults without diabetes and with an estimated glomerular filtration rate (eGFR) of 25–60 mL/min/1.73 m2, who initiated the SGLT2 inhibitors dapagliflozin or empagliflozin between September 2020 and November 2022 at Maccabi Healthcare Services, an Israeli health maintenance organization. We assessed the effects of SGLT2 inhibitors on renal function (changes in eGFR slope/time). Index date was defined as the date of the first dispensing of SGLT2 inhibitors. Annual baseline slope was calculated using all eGFR measurements during the 2 years prior to index date (median = 7 measurements), while annual follow‐up slope was calculated from all evaluations during 90–900 days post index date, along with baseline measurement at index date (median = 6 measurements). Paired t tests were used to compare differences between baseline and follow‐up annual slopes. Results: Of a total of 354 participants with CKD, without diabetes, who received SGLT2 inhibitors and were followed for a median of 527 days, the mean age was 72.8 ± 11.8 years, 26% were female, and 91% used renin‐angiotensin system blockade. The mean eGFR was 45.4 ± 9.5 mL/min/1.73 m2. The mean body mass index was 29.1 ± 5.4 kg/m2. During the year before index date, 146 participants (41%) had a urinary albumin to creatinine ratio (UACR) <30 mg/g, 81 (23%) had a UACR of 30–300 mg/g, 74 (21%) had a UACR >300 mg/g, and 53 (15%) had no UACR evaluation. The mean eGFR slope over time was −5.6 ± 7.7 mL/min/1.73 m2 per year at baseline, which improved to −1.7 ± 6.8 mL/min/1.73 m2 per year after SGLT2 inhibitor administration (p <0.001). This effect was independent of UACR. Conclusion: In a real‐world study of primarily older non‐diabetic adults with CKD, SGLT2 inhibition was associated with a slower rate of kidney function decline, regardless of baseline UACR level. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Reconstituted HDL ameliorated renal injury of diabetic kidney disease in mice.
- Author
-
Tao, Yu, Lacko, Andras G., Sabnis, Nirupama A., Das‐Earl, Paromita, Ibrahim, Deena, Crowe, Nicole, Zhou, Zhengyang, Cunningham, Mark, Castillo, Angie, and Ma, Rong
- Subjects
- *
DIABETIC nephropathies , *RENAL fibrosis , *KIDNEY cortex , *KIDNEY injuries , *MICE , *FIBRONECTINS - Abstract
Diabetic kidney disease (DKD) is a devastating kidney disease and lacks effective therapeutic interventions. The present study was aimed to determine whether reconstituted high‐density lipoprotein (rHDL) ameliorated renal injury in eNOS−/−dbdb mice, a mouse model of DKD. Three groups of mice, wild type C57BLKS/J (non‐diabetes), eNOS−/−dbdb (diabetes), and eNOS−/−dbdb treated with rHDL (diabetes+rHDL) with both males and females were used. The rHDL nanoparticles were administered to eNOS−/−dbdb mice at Week 16 at 5 μg/g body weight in ~100 μL of saline solution twice per week for 4 weeks via retroorbital injection. We found that rHDL treatment significantly blunted progression of albuminuria and GFR decline observed in DKD mice. Histological examinations showed that the rHDLs significantly alleviated glomerular injury and renal fibrosis, and inhibited podocyte loss. Western blots and immunohistochemical examinations showed that increased protein abundances of fibronectin and collagen IV in the renal cortex of eNOS−/−dbdb mice were significantly reduced by the rHDLs. Taken together, the present study suggests a renoprotective effect of rHDLs on DKD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Potential kidney protective effects of glucagon‐like peptide‐1 receptor agonists.
- Author
-
Trevella, Philippa, Ekinci, Elif I., and MacIsaac, Richard J.
- Subjects
- *
GLUCAGON-like peptide-1 receptor , *GLUCAGON-like peptide-1 agonists , *CHRONIC kidney failure , *TYPE 2 diabetes , *KIDNEYS - Abstract
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes (T2DM) with chronic kidney disease (CKD). This class of medication has demonstrated promising results in reducing albuminuria, preserving estimated glomerular filtration rate (eGFR), and mitigating cardiovascular (CV) risk, making them potential therapeutic options for individuals with CKD. The kidney protective effects of GLP‐1RAs extend beyond glycaemic control, and are thought to be attributed to their anti‐inflammatory, antioxidant, and natriuretic properties. Despite these promising findings, the use of GLP‐RAs has yet to be definitively shown to slow progression to chronic kidney failure, or reduce CV and kidney related death in people with T2DM and CKD. The Research Study to See How Semaglutide (a once weekly subcutaneous administered GLP‐1RA) Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease (FLOW trial) was recently stopped because of efficacy. The primary end point for the FLOW trial consists of a composite endpoint of (i) onset of chronic kidney failure; (ii) death from kidney failure; (iii) cardiovascular death; and (iv) onset of a persistent ≥50% reduction in eGFR from baseline. It has also been reported by the sponsors of the trial that the primary end point of the trial was reduced by 24% with both CKD and CV outcomes contributing to risk reduction. In anticipation of the results of the FLOW trial being published, we review the current evidence surrounding kidney outcomes and proposed kidney protective pathways associated with GLP‐1RA use. Summary at a glance: In anticipation of the results of a dedicated kidney outcome study of the GLP‐1RA semaglutide in people with type 2 diabetes and established chronic kidney disease (the FLOW trial) being released sometime in 2024, here we review the current evidence surrounding kidney outcomes and proposed kidney protective pathways associated with GLP‐1RA use. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Cost-effectiveness Analysis of Lercanidipine Compared to Amlodipine as an Addition to Renin-angiotensin System Blockers in Diabetic Hypertensive Patients with Albuminuria in Thailand.
- Author
-
Russameeruttayadham, Kamolpat, Thavornwattanayong, Wiwat, Ueapanjasin, Piyanut, and Lertsirimunkong, Jadesada
- Subjects
RENIN-angiotensin system ,ALBUMINURIA ,AMLODIPINE ,DIABETES complications ,COST effectiveness ,HYPERTENSION - Abstract
Objective: Dihydropyridine calcium channel blocker (DHP-CCBs) is an appropriate add-on antihypertensive option for uncontrolled blood pressure diabetic hypertensive patients with albuminuria who are already taking renin-angiotensin system blockers (RASBs). Among DHP-CCBs, amlodipine is the first-line medication in combination with RASBs. However, new-generation DHP-CCBs like lercanidipine has demonstrated superior effectiveness and fewer side effects, although at a higher cost than amlodipine. This study aims to assess the cost-effectiveness of lercanidipine versus amlodipine when added to RASBs in diabetic hypertensive patients with albuminuria. The objective is to provide robust evidence guiding the selection of the most suitable and worthwhile treatment option in Thailand. Materials and Methods: This study analyses the cost-effectiveness of lercanidipine versus amlodipine as an addition to RASBs in diabetic hypertensive patients with albuminuria. The analysis was conducted from a societal perspective using a Markov model. Results: The total costs of lercanidipine and amlodipine treatments were 370,392.83 baht and 384,221.85 baht, respectively. The life years gained for lercanidipine and amlodipine treatments were 11.33 years and 10.96 years respectively. Additionally, the quality-adjusted life years (QALYs) of lercanidipine and amlodipine treatments were 8.06 years and 7.51 years respectively. The calculated ICER was negative, indicating treatment with lercanidipine as a dominant strategy. Conclusion: Due to lercanidipine’s noticeable cost-effectiveness, lower costs, and longer QALYs. Adding lercanidipine has proven to be more cost-effective than amlodipine for diabetic hypertensive patients with albuminuria who have been unable to achieve their blood pressure goals with RASBs alone. Therefore, lercanidipine should be the preferred choice as an add-on to RASBs in Thailand. These results could significantly aid policymakers in making informed decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis.
- Author
-
Sehtman‐Shachar, Dvora R., Yanuv, Ilan, Schechter, Meir, Fishkin, Alisa, Aharon‐Hananel, Genya, Leibowitz, Gil, Rozenberg, Aliza, and Mosenzon, Ofri
- Subjects
- *
MORTALITY , *CORONARY disease , *ALBUMINS , *ODDS ratio , *ALBUMINURIA ,CARDIOVASCULAR disease related mortality - Abstract
Aim Materials and Methods Results Conclusions To assess the association between urinary albumin‐to‐creatinine ratio (UACR) categories within the normal range with mortality and adverse cardiovascular outcomes.PubMed and Embase were systematically searched for real‐world evidence studies. Studies were manually evaluated according to predefined eligibility criteria. We included prospective and retrospective cohort studies of the association between UACR categories <30 mg/g and cardiovascular outcomes or mortality. Published information regarding study design, participants, UACR categorization, statistical methods, and results was manually collected. Two UACR categorization approaches were defined: a two‐category (UACR <10 mg/g vs. 10‐30 mg/g) and a three‐category division (UACR <5 mg/g vs. 5‐10 and 10‐30 mg/g). A random effects meta‐analysis was performed on studies eligible for the meta‐analysis.In total, 22 manuscripts were identified for the systematic review, 15 of which were eligible for the meta‐analysis. The results suggest an association between elevated UACR within the normal to mildly increased range and higher risks of all‐cause mortality, cardiovascular death, and coronary heart disease, particularly in the range of 10‐30 mg/g. Compared with UACR <10 mg/g, the hazard ratio [HR (95% confidence interval, CI)] for UACR between 10 and 30 mg/g was 1.41 (1.15, 1.74) for all‐cause mortality and 1.56 (1.23, 1.98) for coronary heart disease. Compared with UACR <5 mg/g, the risk of cardiovascular mortality for UACR between 10 and 30 mg/g was more than twofold [HR (95% CI): 2.12 (1.61, 2.80)]. Intermediate UACR (5‐10 mg/g) was also associated with a higher risk of all‐cause mortality [HR (95% CI): 1.14 (1.05, 1.24)] and cardiovascular mortality [HR (95% CI): 1.50 (1.14, 1.99)].We propose considering higher UACR within the normoalbuminuric range as a prognostic factor for cardiovascular morbidity and mortality. Our findings underscore the clinical significance of even mild increases in albuminuria. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Persistent albuminuria and chronic kidney disease in adults with sickle cell anaemia: Results from a multicenter natural history study.
- Author
-
Zhou, Laura Y., Derebail, Vimal K., Desai, Payal C., Elsherif, Laila, Patillo, Kammie L., McCune, Paula, Wichlan, David, Landes, Kristina, Ogu, Ugochi O., Nelson, Marquita, Loehr, Laura R., Cronin, Robert M., Tang, Yihan, Cai, Jianwen, and Ataga, Kenneth I.
- Subjects
- *
SICKLE cell anemia , *CHRONIC kidney failure , *ALBUMINURIA , *LOGISTIC regression analysis , *GLOMERULAR filtration rate - Abstract
Summary Clinical and laboratory correlates of chronic kidney disease (CKD) in sickle cell anaemia remain incompletely defined. In a multicenter cohort study, we evaluated the prevalence of persistent albuminuria (PA) and characteristics associated with PA, albumin–creatinine ratio (ACR) and decreased estimated glomerular filtration rate (eGFR) using logistic, linear and multinomial regression models, respectively. Of 269 participants (median age: 30 years; 57.2% females), the prevalence of PA was 35.7%. Using baseline ACR values of <100 and ≥100 mg/g, the probabilities of PA were 30.0% and 94.6%, respectively. In multivariable logistic regression analyses, male sex (β = 0.80 [SE = 0.36], p = 0.024) and ACE inhibitors/ARBs use (β = 1.54 [SE = 0.43], p < 0.001) were associated with higher likelihoods of PA, while higher haemoglobin (β = −0.33 [SE = 0.13], p = 0.009) and HbF (β = −0.04 [SE = 0.02], p = 0.041) were associated with lower likelihoods of PA. In multivariable multinomial regression analyses, older age (β = 0.06 [SE = 0.02], p = 0.004) and higher alkaline phosphatase (β = 0.01 [SE = 0.00], p = 0.004) were associated with higher odds of having eGFR 60–90 versus eGFR>90 mL/min/1.73 m2 using the cystatin C‐based CKD‐EPI‐2012 equation. Additionally, higher systolic blood pressure (β = 0.11 [SE = 0.03], p = 0.001) and blood urea nitrogen (β = 0.45 [SE = 0.12], p < 0.001) were associated with higher odds, while higher haemoglobin (β = −1.22 [SE = 0.43], p = 0.004) was associated with lower odds of having eGFR<60 versus eGFR>90 mL/min/1.73 m2. PA and decreased eGFR are associated with measures of disease severity and comorbid conditions (Clinicaltrials.gov Identifier: NCT03277547). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Using eGFR and Albumin Creatinine Ratio as an Initial Screening Tool in Trinidadian Primary Care to Identify High-risk Population for CKD: A Cross-Sectional Study.
- Author
-
Mahadevappa, Karthik, Nayak, Shivananda B., Maharaj, Rohan G., and Bhaktha, Geetha
- Subjects
- *
RISK assessment , *CROSS-sectional method , *CREATININE , *RESEARCH funding , *ALBUMINURIA , *PRIMARY health care , *HYPERTENSION , *AGE distribution , *CHRONIC kidney failure , *NON-communicable diseases , *TYPE 2 diabetes , *MEDICAL screening , *ALBUMINS , *GLOMERULAR filtration rate , *COMORBIDITY , *DISEASE risk factors - Abstract
Background: Chronic kidney disease (CKD) is a major public health burden and is often undiagnosed in the primary care setting. Untested and untreated, this often leads to renal failure and dialysis. Materials and Methods: This was a cross-sectional study of adults aged 20 years and over, diagnosed with type 2 diabetes mellitus and/or hypertension, with no previous history or record of CKD, and attending three chronic disease clinics in the Eastern Regional Health Authority (ERHA). Patients were screened for risk of CKD by using the albumin creatinine ratio. The eGFR was calculated based on serum creatinine by using the CKD Epidemiology Collaboration (EPI) 2009 equation. Results: In total, 430 patients agreed to participate with 61.2% of response rate. Of the 385 with complete data, 357 (92%) were detected as having a high risk for CKD; older patients (>66 years) and those with both diabetes and hypertension had high proportions of risk for CKD. There were significant associations between age, systolic hypertension, and the severity of risk for CKD. Conclusion: CKD is common at the primary care level among adults with NCDs in Trinidad, with many patients having been left out without being tested for CKD. Primary care physicians must take this into consideration in caring for NCD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Prevalence of chronic kidney disease in children of school going age visiting outpatient department of A Tertiary Care Hospital in Karachi, Pakistan.
- Author
-
Parker, Erum, Khan, Mashal, and Abroo, Bilqis
- Subjects
- *
SCHOOL children , *PEDIATRIC nephrology , *BLOOD urea nitrogen , *CHRONIC kidney failure , *KIDNEY diseases - Abstract
Objective: To determine the prevalence of chronic kidney disease (CKD) among children of school-going age. Study Design: Cross-sectional study. Setting: Department of Pediatric Medicine, National Institute of Child Health, Karachi, Pakistan. Period: July 2023 to December 2023. Methods: A total of 130 children of both genders, aged between 5-15 years, visiting outpatient department of pediatric medicine were analyzed. Demographic and clinical information were noted. Laboratory investigations like urinalysis and serum creatinine were performed. CKD was diagnosed on the basis of "Kidney Disease Outcomes Quality Initiative (KDOQI)" guidelines. Results: In a total of 130 children, 67 (51.5%) children were male. Overall, the mean age was 8.43±2.45 years. Hypertension was diagnosed in 10 (7.7%) children. Anemia was present in 103 (79.2%) patients. The mean hemoglobin, serum creatinine, and blood urea nitrogen were 9.41±1.98 g/dl, 0.48±0.37 mg/dl, and 34.20±33.18 mg/dl, respectively. CKD was diagnosed in 10 (7.7%) children. Among these 10 children diagnosed with CKD, 7 were having CKD stage-1 whereas CKD stage-2 was noted in 3 children. Presence of hypertension (p=0.006), and albuminuria (p<0.001) were associated with CKD. Conclusion: The prevalence of CKD in school going age children was 7.7%. Presence of hypertension, and albuminuria were linked with CKD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Prevalence of kidney health genetic variants in adults with sickle cell nephropathy.
- Author
-
Ruiz, Maria Armila, Zhang, Xu, Mansilla, M. Adela, Zahr, Rima S., Thomas, Christie P., Smith, Richard J., Gordeuk, Victor R., and Saraf, Santosh L.
- Subjects
- *
GENETIC variation , *SICKLE cell anemia , *KIDNEY diseases , *ADULTS , *GLOMERULAR filtration rate , *NEPHROLOGY - Abstract
Summary: The pathophysiology and genetic risk for sickle cell disease (SCD)‐related chronic kidney disease (CKD) are not well understood. In 70 adults with SCD‐related CKD and without APOL1 inherited in a high‐risk pattern, 24 (34%) had pathogenic variants in candidate genes using KidneySeq™. A moderate impact INF2 variant was observed in 20 (29%) patients and those with 3 versus 0–2 pathogenic or moderate impact glomerular genetic variants had higher albuminuria and lower estimated glomerular filtration rate (adjusted p ≤ 0.015). Using a panel of preselected genes implicated in kidney health, we observed several variants in people with sickle cell nephropathy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Association of visceral adipose tissue with albuminuria and interaction between visceral adiposity and diabetes on albuminuria.
- Author
-
Liu, Yufang, Zhao, Dan, Chai, Sanbao, and Zhang, Xiaomei
- Subjects
- *
ALBUMINURIA , *ADIPOSE tissues , *HEALTH & Nutrition Examination Survey , *DUAL-energy X-ray absorptiometry - Abstract
Aims: To explore the correlation between visceral adipose tissue and albuminuria, and whether there is interaction between visceral adipose tissue and diabetes on albuminuria. Methods: The study subjects were adult subjects (age ≥ 18 years) from the National Health and Nutrition Examination Surveys (NHANES) database of the USA in 2017–2018. Visceral fat area (VFA) was measured by dual-energy X-ray absorptiometry (DXA). Subjects were divided into three groups according to VFA: low (VFA 0–60cm2), medium (VFA 60–120 cm2) and high (VFA ≥ 120 cm2). Albuminuria was defined as urinary albumin-to-creatinine ratio (UACR) ≥ 30 mg/g. The statistical analysis software used is STATA 17.0. Results: Data pertaining to 2965 participants (2706 without albuminuria) were included in the analysis. High VFA is an independent risk factor for albuminuria (OR 1.367, 95% CI 1.023–1.827). In the low-VFA group, there is no significant association between diabetes and albuminuria (OR 1.415, 95% CI 0.145–13.849). In the medium-VFA group, diabetes is an independent risk factor for albuminuria (OR 2.217, 95% CI 1.095–4.488). In the high-VFA group, diabetes is also an independent risk factor for albuminuria (OR 5.150, 95% CI 3.150–8.421). There is an additive interaction between high VFA (VFA ≥ 120 cm2) and diabetes on the effect of albuminuria (RERI 3.757, 95% CI 0.927–6.587, p = 0.009), while no multiplication interaction (OR 1.881, 95% CI 0.997–1.023, p = 0.141). Conclusions: High VFA may represent an independent risk factor for albuminuria. The amount of visceral fat may affect the effect of diabetes on albuminuria. The higher the visceral fat, the stronger the correlation between diabetes and albuminuria should be present. We suppose an additive interaction between VFA and diabetes on the effect of albuminuria. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. INCIDENCE AND RISK FACTORS FOR PROGRESSION TO END-STAGE RENAL DISEASE IN PATIENTS WITH DIABETIC NEPHROPATHY: A PROSPECTIVE OBSERVATIONAL STUDY.
- Author
-
Krishna Hareesh, Mitta Venkata
- Subjects
- *
GLYCEMIC control , *CHRONIC kidney failure , *DISEASE risk factors , *PEOPLE with diabetes , *ALBUMINURIA , *DIABETIC nephropathies - Abstract
Background: Diabetic nephropathy is a leading cause of end-stage renal disease (ESRD) worldwide. Identifying the incidence and risk factors for progression to ESRD in patients with diabetic nephropathy is crucial for effective clinical management. Objective: This prospective observational study aimed to determine the incidence and identify risk factors for progression to ESRD in patients with diabetic nephropathy. Materials and Methods: A total of 50 patients with diabetic nephropathy were recruited from 2018 to 2022 and followed for two years. Baseline demographic and clinical characteristics were collected. The primary outcome was progression to ESRD. Multivariate Cox proportional hazards regression analysis was used to identify significant risk factors for progression to ESRD. Results: The mean age of the patients was 60.4 ± 10.2 years, with 30 males (60%) and 20 females (40%). The average duration of diabetes was 15.8 ± 6.7 years. Baseline eGFR was 45.3 ± 12.6 mL/min/1.73 m², and baseline albuminuria was 430 ± 230 mg/g. During the follow-up period, 12 patients (24%) progressed to ESRD. Significant risk factors for progression included lower baseline eGFR (HR: 1.95; 95% CI: 1.12-3.42; p=0.01), higher baseline albuminuria (HR: 1.68; 95% CI: 1.03-2.75; p=0.04), and longer duration of diabetes (HR: 1.22; 95% CI: 1.05-1.41; p=0.02). Blood pressure control had a protective effect but was not statistically significant (HR: 0.75; 95% CI: 0.50- 1.12; p=0.16). Glycemic control showed no significant association with progression to ESRD (HR: 0.98; 95% CI: 0.87-1.10; p=0.72). Conclusion: This study highlights the high incidence of progression to ESRD in patients with diabetic nephropathy and underscores the importance of monitoring baseline eGFR, albuminuria, and diabetes duration. Early interventions targeting these risk factors may reduce ESRD progression. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Use of kidney failure risk equation as a tool to evaluate referrals from primary care to specialist nephrology care.
- Author
-
Li, Katherine, Pirabhahar, Saiyini, Thomsett, Max, Turner, Kylie, Wainstein, Marina, Ha, Jeffrey T., and Katz, Ivor
- Subjects
- *
KIDNEY failure , *MEDICAL specialties & specialists , *CREATININE , *T-test (Statistics) , *ALBUMINURIA , *PRIMARY health care , *SEVERITY of illness index , *RETROSPECTIVE studies , *TERTIARY care , *DESCRIPTIVE statistics , *NEPHROLOGY , *LONGITUDINAL method , *KIDNEY diseases , *DATA analysis software , *MEDICAL referrals , *MEDICAL care costs , *DIABETES , *GLOMERULAR filtration rate , *DISEASE risk factors - Abstract
Background: With rising costs and burden of chronic kidney disease (CKD), timely referral of patients to a kidney specialist is crucial. Currently, Kidney Health Australia (KHA) uses a 'heat map' based on severity and not future risk of kidney failure, whereas the kidney failure risk equation (KFRE) score predicts future risk of progression. Aims: Evaluate whether a KFRE score assists with timing of CKD referrals. Methods: Retrospective cohort of 2137 adult patients, referred to tertiary hospital outpatient nephrologist between 2012 and 2020, were analysed. Referrals were analysed for concordance with the KHA referral guidelines and, with the KFRE score, a recommended practice. Results: Of 2137 patients, 626 (29%) did not have urine albumin‐to‐creatinine ratio (UACR) measurement at referral. For those who had a UACR, the number who met KFRE preferred referral criteria was 36% less than KHA criteria. If the recommended KFRE score was used, then fewer older patients (≥40 years) needed referral. Positively, many diabetes patients were referred, even if their risk of kidney failure was low, and 29% had a KFRE over 3%. For patients evaluated meeting KFRE criteria, a larger proportion (76%) remained in follow‐up, with only 8% being discharged. Conclusions: KFRE could reduce referrals and be a useful tool to assist timely referrals. Using KFRE for triage may allow those patients with very low risk of future kidney failure not be referred, remaining longer in primary care, saving health resources and reducing patients' stress and wait times. Using KFRE encourages albuminuria measurement. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Real-Life Experience on the Effect of SGLT2 Inhibitors vs. Finerenone vs. Combination on Albuminuria in Chronic Kidney Disease.
- Author
-
Hanouneh, Mohamad, Le, Dustin, Jaar, Bernard G., Tamargo, Christina, and Cervantes, C. Elena
- Subjects
- *
ACE inhibitors , *ANGIOTENSIN-receptor blockers , *MINERALOCORTICOID receptors , *CHRONIC kidney failure , *TYPE 2 diabetes - Abstract
Background: There have been several recent advances in the care of patients with chronic kidney disease (CKD), including the use of sodium glucose cotransporter 2 (SGLT2) inhibitors and selective mineralocorticoid receptor antagonists (MRAs). There are very few data reporting the outcomes of these treatments in real-world experience. The aim of this retrospective study is to report the effects of SGLT2 inhibitors, finerenone, and their combination in CKD patients in our community-based setting. Methods: Ninety-eight patients with CKD with an estimated glomerular filtration rate (eGFR) between 25 and 90 mL/min per 1.73 m2 and a urine albumin-to-creatinine ratio (UACR) ≥ 30 mg/g were included. Patients were divided into three groups: two monotherapy groups of SGLT2 inhibitors or finerenone and a third combination group of therapy with SGLT2 inhibitors for the first 4 months and SGLT2 inhibitors and finerenone subsequently. The primary outcomes were the timing and percentage of patients achieving a >50% reduction in UACR from baseline. Results: Group 1 comprised 52 patients on SGLT2i, group 2 had 22 patients on finerenone, and group 3 had 24 patients on combination therapy. The baseline median UACR and mean eGFR were 513 mg/g and 47.9 mL/min per 1.73 m2 in group 1, 548.0 mg/g and 50.5 mL/min per 1.73 m2 in group 2, and 800 mg/g and 60 mL/min per 1.73 m2 in group 3. At baseline, 71 (72.4%) patients were on the angiotensin-converting enzyme inhibitor (ACEi) or the angiotensin receptor blocker (ARB), and 78 (79.5%) patients had type 2 diabetes. After 8 months of follow-up, a >50% decrease in albuminuria was achieved in 96% of patients in group 3, compared to 50% in group 1 and 59% in group 2 (p-values were <0.01 and <0.01, respectively). There was a statistically but not clinically significant change in mean potassium levels in group 2 (+0.4 mmol/L) compared to either group 1 (0.0 mmol/L with p-value: <0.01) or group 3 (−0.01 mmol/L with p-value: <0.01). However, there was no difference in potassium levels when comparing groups 1 and 3. At the end of the follow-up, the average difference in eGFR was −3.4 (8.8), −5.3(10.1), and −7.8 (11.2) mL/min per 1.73 m2 in groups 1, 2, and 3, respectively, without a statistically significant difference between groups. Conclusions: In this real-world experience in our community setting, the combination of SGLT2 inhibitors and finerenone in our adult patients with CKD was associated with a very significant and clinically relevant reduction in UACR, without an increased risk of hyperkalemia. Combination therapy of SGLT2 inhibitor and finerenone regarding background use of ACEi/ARB is feasible and should be encouraged for further albuminuria reductions in CKD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Evaluating Serum Apelin and Nitric Oxide in Primary Hypertensive Patients with or without Microalbuminuria: A Cross-sectional Study.
- Author
-
PANDA, MRUTYUNJAYA, PANDIT, DEBASISH, PRADHAN, DEVI PRASAD, RATTAN, ROMA, and MANDAL, MANMATH KUMAR
- Subjects
- *
HYPERTENSION , *APELIN , *ALBUMINURIA , *HDL cholesterol , *LDL cholesterol - Abstract
Introduction: Hypertension (HTN) is the third leading risk factor contributing to the disease burden in Southeast Asia. Understanding its underlying mechanism, such as endothelial dysfunction, is very important. Apelin is a recently discovered endogenous peptide hormone that, along with Nitric Oxide (NO), is implicated in endothelial dysfunction and the severity of HTN. This can significantly reduce renal function and lead to microalbuminuria/proteinuria in 5-15% of patients. Aim: To measure serum apelin and NO in patients with newly diagnosed primary HTN with or without microalbuminuria and to investigate the correlation of serum apelin with HTN in the same study population. Materials and Methods: This cross-sectional study was conducted from February 2019 to January 2021 in the Department of Biochemistry In collaboration with the Department of Medicine at SCB Medical College and Hospital, Cuttack, Odisha, India. A total of 180 participants were included in the present study. Among them, 90 were newly diagnosed hypertensive patients, and 90 were non hypertensive. The study comprised of 90 hypertensive patients, with 46 having microalbuminuria (Group-A), 44 without microalbuminuria (Group-B) and 90 normotensive controls (Group-C). All participants underwent evaluation of their biochemical profile which included Fasting Plasma Sugar (FBS), serum urea, creatinine, Total Cholesterol (TC), Triglyceride (TG), High-density Lipoprotein cholesterol (HDL-c), Low-density Lipoprotein cholesterol (LDL-c), Very Low-Density Lipoprotein (VLDL), serum apelin and NO levels, and urine albumin. The comparison between the three groups was done by using Analysis of Variance (ANOVA) test with post-hoc analysis. The Chi-square test was used to compare categorical variables. Results: The mean age of the participants was 50.48±9.73 years. study comprised of 90 hypertensive patients, with 46 having microalbuminuria, 44 without microalbuminuria, and 90 normotensive controls. The mean serum apelin levels were 394.45±84.2, 386.9±86.12, and 62.73±22.87 ng/L, respectively, among patients with microalbuminuria, without microalbuminuria, and normotensive patients. Similarly, the mean serum NO levels were 6.31±2.94, 8.32±2.63, and 20.15±4.37 µmol/L, respectively, among the three groups. The comparison of mean values indicated a significant (p<0.001) positive correlation between the level of serum apelin and HTN and its complications, such as microalbuminuria. Conclusion: The positive correlation between serum apelin levels and blood pressure underscores the potential role of apelin in hypertensive pathophysiology. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. The impact of mild and moderate COVID-19 infection on the progression of kidney dysfunction in patients with IgA nephropathy.
- Author
-
Hui, Miao, Shi, Su-Fang, Zhou, Xu-Jie, Liu, Li-Jun, Lv, Ji-Cheng, and Zhang, Hong
- Subjects
- *
SARS-CoV-2 , *COVID-19 , *IGA glomerulonephritis , *CHRONIC kidney failure , *COVID-19 pandemic - Abstract
Background Previous research indicates that coronavirus disease 2019 (COVID-19) infection may have a role in triggering immunoglobulin A (IgA) nephropathy. However, limited research has explored the clinical implications of COVID-19 infection in individuals already diagnosed with IgA nephropathy. This study aimed to determine whether COVID-19 infection independently affects the subsequent trajectory of kidney function in IgA nephropathy patients. Methods This was a single-center cohort study. The study included 199 patients diagnosed with IgA nephropathy. The COVID-19 infection status was determined using a combined method: a questionnaire and the Health Code application, both administered at the end of 2022 in northern China. Kidney function trajectory was assessed by the estimated glomerular filtration rate (eGFR), calculated based on serum creatinine levels measured during follow-up outpatient visits. The primary endpoint of interest was the eGFR trajectory. Results Out of the 199 participants, 75% (n = 181) reported a confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, determined through antigen or polymerase chain reaction tests, accounting for 79% (n = 143) of the infected patients. A significant majority (98%) experienced mild to moderate symptoms. Over a median follow-up period of 10.7 months post-COVID-19 infection, notable clinical events included gross hematuria in 30 patients (16.6%), which normalized within an average of 3 days. Additionally, a 2-fold increase in proteinuria or progression to the nephrotic range was observed in 10 individuals (5.5%). No cases of acute kidney injury were noted. COVID-19 exposure was associated with an absolute change in eGFR of 2.98 mL/min/1.73 m2 per month (95% confidence interval 0.46 to 5.50). However, in a fully adjusted model, the estimated changes in eGFR slope post-COVID-19 were –0.39 mL/min/1.73 m2 per month (95% confidence interval –0.83 to 0.06, P = .088) which included the possibility of no significant effect. Notably, a higher rate of kidney function decline was primarily observed in patients with a baseline eGFR <45 mL/min/1.73 m2 [–0.56 mL/min/1.73 m2 (–1.11 to –0.01), P = .048]. In the cohort, there were few instances of severe COVID-19 cases. The absence of long-term follow-up outcomes was observed. Conclusions Overall, mild to moderate COVID-19 infection does not appear to significantly exacerbate the subsequent decline in kidney function among IgA nephropathy patients, particularly in those with preserved baseline kidney function. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Long-term outcomes of adults with FSGS in the German Chronic Kidney Disease cohort.
- Author
-
Stamellou, Eleni, Nadal, Jennifer, Hendry, Bruce, Mercer, Alex, Bechtel-Walz, Wibke, Schiffer, Mario, Eckardt, Kai-Uwe, Kramann, Rafael, Moeller, Marcus J, Floege, Jürgen, and investigators, GCKD study
- Subjects
- *
MAJOR adverse cardiovascular events , *PROPORTIONAL hazards models , *DISEASE risk factors , *CHRONIC kidney failure , *RENAL replacement therapy - Abstract
Background Focal segmental glomerulosclerosis (FSGS) can lead to kidney failure in adults. This study examines the progression of FSGS in the German Chronic Kidney Disease (GCKD) cohort. Methods The GCKD study (N = 5217), a prospective cohort, included 159 patients with biopsy-confirmed FSGS recruited from 2010 to 2012. Baseline was defined as the first study visit. Adjudicated endpoints included a composite kidney endpoint (CKE), including an estimated glomerular filtration rate (eGFR) decrease >40%, eGFR <15 ml/min/1.73 m2 or initiation of kidney replacement therapy and combined major adverse cardiovascular events (MACE), including non-fatal myocardial infarction or stroke and all-cause mortality. Associations between baseline demographics, laboratory data, comorbidity and CKE and MACE were analysed using the Cox proportional hazards regression model. Results The mean age at baseline was 52.1 ± 13.6 years, with a disease duration of 4.72 years (quartile 1: 1; quartile 3: 6) before joining the study. The median urinary albumin:creatinine ratio (UACR) at baseline was 0.7 g/g (IQR 0.1;1.8), while mean eGFR was 55.8 ± 23 ml/min/1.73 m2. Based on clinical and pathological features, 69 (43.4%) patients were categorized as primary FSGS, 55 (34.6%) as secondary FSGS and 35 (22%) as indeterminate. Over a follow-up of 6.5 years, 44 patients reached the composite kidney endpoint and 16 individuals had at least one MACE. UACR ≥0.7 g/g was strongly associated with both the composite kidney endpoint {hazard ratio [HR] 5.27 [95% confidence interval (CI) 2.4–11.5]} and MACE [HR 3.37 (95% CI 1.05–10.82)] compared with <0.7 g/g, whereas a higher eGFR at baseline (per 10 ml/min) was protective for both endpoints [HR 0.8 (95% CI 0.68–0.95) and HR 0.63 (95% CI 0.46–0.88), respectively]. Patients with secondary FSGS experienced a greater rate of eGFR decline than patients with primary FSGS. Conclusions Lower eGFR and higher albuminuria are key risk factors for kidney disease progression and cardiovascular events in patients with FSGS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. A meta-analysis of urinary transferrin for early diagnosis of diabetic nephropathy.
- Author
-
Li, Bangjian, Wang, Jieying, and Ye, Wen
- Subjects
- *
PUBLIC health surveillance , *PROTEINURIA , *TRANSFERRIN , *RECEIVER operating characteristic curves , *ALBUMINURIA , *CREATININE , *DIABETIC nephropathies , *ENZYME-linked immunosorbent assay , *META-analysis , *BLOOD urea nitrogen , *SYSTEMATIC reviews , *MEDLINE , *MEDICAL databases , *MEDICAL records , *ACQUISITION of data , *EARLY diagnosis , *MEDICAL screening , *ONLINE information services , *DATA analysis software , *BIOMARKERS , *MEDICAL practice , *SENSITIVITY & specificity (Statistics) - Abstract
Objective To assess the diagnostic value of urinary transferrin (Tf) in early diabetic nephropathy (DN) to propose a more sensitive and noninvasive biomarker for screening and monitoring DN in clinical practice. Methods We searched 3 databases from their inception to May 2023, to identify studies investigating the diagnostic value of Tf in patients with DN. Meta-DiSc software, version 1.4, and Stata software, version 15.1 (StataCorp) were used to conduct a meta-analysis and evaluate the diagnostic accuracy of urine Tf levels for DN. Results The meta-analysis included 6 relevant studies investigating the diagnostic value of Tf level for DN. Urinary Tf as a diagnostic marker demonstrated a combined sensitivity of 0.82 (95% CI, 0.71-0.89) and specificity of 0.88 (0.84-0.92). the positive diagnostic likelihood ratio was 7.07 (4.57-10.93), the negative diagnostic likelihood ratio was 0.20 (0.12-0.35), and the diagnostic odds ratio was 34.49 (13.61-87.44). Also, the area under the receiver operating characteristic curve was 0.92 (0.89-0.94), indicating that urinary Tf has a decent discriminative ability in diagnosing DN. Conclusion Tf level is a valuable biological marker for early diagnosis and monitoring of DN in clinical practice. It has statistically significant predictive value for patients in the early phases of DN. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Ability of NAD and Sirt1 to epigenetically suppress albuminuria.
- Author
-
Hasegawa, Kazuhiro, Tamaki, Masanori, Shibata, Eriko, Inagaki, Taizo, Minato, Masanori, Yamaguchi, Sumiyo, Shimizu, Ikuko, Miyakami, Shinji, Tada, Miho, and Wakino, Shu
- Subjects
- *
SIRTUINS , *ALBUMINURIA , *DIABETIC nephropathies , *CLAUDINS , *METABOLITES - Abstract
The time for diabetic nephropathy (DN) to progress from mild to severe is long. Thus, methods to continuously repress DN are required to exert long-lasting effects mediated through epigenetic regulation. In this study, we demonstrated the ability of nicotinamide adenine dinucleotide (NAD) and its metabolites to reduce albuminuria through Sirt1- or Nampt-dependent epigenetic regulation. We previously reported that proximal tubular Sirt1 was lowered before glomerular Sirt1. Repressed glomerular Sirt1 was found to epigenetically elevate Claudin-1. In addition, we reported that proximal tubular Nampt deficiency epigenetically augmented TIMP-1 levels in Sirt6-mediated pathways, leading to type-IV collagen deposition and diabetic fibrosis. Altogether, we propose that the Sirt1/Claudin-1 axis may be crucial in the onset of albuminuria at the early stages of DN and that the Nampt/Sirt6/TIMP-1 axis promotes diabetic fibrosis in the middle to late stages of DN. Finally, administration of NMN, an NAD precursor, epigenetically potentiates the regression of the onset of DN to maintain Sirt1 and repress Claudin-1 in podocytes, suggesting the potential use of NAD metabolites as epigenetic medications for DN. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Associations of Insulin Resistance and High-Sensitivity C-Reactive Protein with Metabolic Abnormalities in Korean Patients with Type 2 Diabetes Mellitus: A Preliminary Study.
- Author
-
Jeong, Yuchul, Lee, Beom Jun, Hur, Wonjai, Lee, Minjoon, and Han, Se-Hyeon
- Subjects
TYPE 2 diabetes ,GLYCOSYLATED hemoglobin ,DIASTOLIC blood pressure ,CAROTID intima-media thickness ,INSULIN resistance ,ASPARTATE aminotransferase - Abstract
We conducted this single-center, retrospective, cohort study to examine whether insulin resistance (IR) and high-sensitivity C-reactive protein (hsCRP) have a relationship with metabolic abnormalities in patients with type 2 diabetes mellitus (T2DM). In a total of 3758 patients (n = 3758) with T2DM, we analyzed medical records and thereby evaluated their baseline characteristics such as age, sex, duration of T2DM, systolic blood pressure (SBP), diastolic blood pressure (DBP), waist circumference, body mass index (BMI), visceral fat thickness (VFT), fasting plasma insulin levels, C-peptide levels, glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), homeostatic model assessment of insulin resistance (HOMA-IR), homeostatic model assessment of β-cell function (HOMA-β), aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), albuminuria, intima-media thickness (IMT) and hsCRP. The patients were stratified according to the tertile of the K index of the insulin tolerance test (KITT) or hsCRP. Thus, they were divided into the lowest (≥2.37), middle (1.54–2.36) and highest tertile (0–1.53) of KITT and the lowest (0.00–0.49), middle (0.50–1.21) and highest tertile (≥1.22) of hsCRP. Moreover, associations of KITT and hsCRP with metabolic abnormalities, such as steatotic liver disease (SLD), metabolic syndrome (MetS), albuminuria, diabetic retinopathy and carotid atherosclerosis, were also analyzed. There was a significant positive correlation between the prevalence of SLD, MetS, albuminuria and diabetic retinopathy and KITT (p < 0.001). Moreover, there was a significant positive association between the prevalence of SLD, MetS and albuminuria and hsCRP (p < 0.001). In conclusion, our results indicate that clinicians should consider the relationships of IR and hsCRP with metabolic abnormalities in the management of patients with T2DM. However, further large-scale, prospective, multi-center studies are warranted to confirm our results. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Prediabetes and CKD: Does a causal relationship exist
- Author
-
Jorge Rico Fontalvo, María José Soler, Rodrigo Daza Arnedo, Guillermo Navarro-Blackaller, Ramón Medina-González, Tomas Rodríguez Yánez, Maria Cardona-Blanco, Jose Cabrales-Juan, Isabella Uparrela-Gulfo, and Jonathan S. Chávez-Iñiguez
- Subjects
Prediabetes ,Enfermedad renal crónica ,Albuminuria ,Hiperglicemia ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
The relationship between diabetes and the development of kidney complications is well known, but the understanding of prediabetes and insulin resistance with impaired kidney function has been scarcely assessed. Various factors could explain this phenomenon, from the lack of standardization in the definitions of prediabetes, to the erratic and inconsistent evidence in large-scale epidemiological and cohort studies. It seems that the pathophysiological pathway of prediabetes could be related to inflammation and neurohormonal hyperactivation, factors present even before the onset of diabetes, which might be the main drivers of glomerular hyperfiltration, albuminuria, and impaired glomerular filtration rate. It is possible that existing treatments for the management of diabetes, as metformin or SGLT2 inhibitors may also be useful in patients with prediabetes with evidence of functional and structural kidney damage. The purpose of this review is to summarize the evidence regarding the relationship between prediabetes (preDM) and the development of CKD. Resumen: La relación entre diabetes y el desarrollo de complicaciones renales es bien conocida; sin embargo la asociación entre prediabetes y la resistencia a la insulina con el daño en la función renal apenas ha sido evaluada. Varios factores podrían explicar este fenómeno, desde la falta de estandarización en las definiciones de prediabetes, hasta la errática e inconsistente evidencia en estudios epidemiológicos y de cohortes a gran escala. Parece que las vías fisiopatológicas en la prediabetes podrían estar relacionadas con inflamación y la hiperactivación del sistema neuro-hormonal, factores presentes incluso antes de la aparición de la diabetes, que podrían ser los principales impulsores de la hiperfiltración glomerular, albuminuria y alteración de la tasa de filtración glomerular. Es posible que los tratamientos existentes para el control de la diabetes, como metformina o los inhibidores SGLT2 también pueden ser útiles en pacientes con prediabetes con evidencia de daño renal funcional o estructural. El propósito de esta revisión es resumir la evidencia sobre la relación entre la prediabetes (preDM) y el desarrollo de la ERC.
- Published
- 2024
- Full Text
- View/download PDF
49. Epicardial and liver fat implications in albuminuria: a retrospective study
- Author
-
Carolina M. Perdomo, Nerea Martin-Calvo, Ana Ezponda, Francisco J. Mendoza, Gorka Bastarrika, Nuria Garcia-Fernandez, José I. Herrero, Inmaculada Colina, Javier Escalada, and Gema Frühbeck
- Subjects
Steatotic liver disease ,Epicardial adipose tissue ,Visceral adipose tissue ,Albuminuria ,Chronic kidney disease ,Cardiovascular disease ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background Albuminuria is considered an early and sensitive marker of kidney dysfunction, but also an independent cardiovascular risk factor. Considering the possible relationship among metabolic liver disease, cardiovascular disease and chronic kidney disease, we aimed to evaluate the risk of developing albuminuria regarding the presence of epicardial adipose tissue and the steatotic liver disease status. Methods A retrospective long-term longitudinal study including 181 patients was carried out. Epicardial adipose tissue and steatotic liver disease were assessed by computed tomography. The presence of albuminuria at follow-up was defined as the outcome. Results After a median follow up of 11.2 years, steatotic liver disease (HR 3.15; 95% CI, 1.20–8.26; p = 0.02) and excess amount of epicardial adipose tissue (HR 6.12; 95% CI, 1.69–22.19; p = 0.006) were associated with an increased risk of albuminuria after adjustment for visceral adipose tissue, sex, age, weight status, type 2 diabetes, prediabetes, hypertriglyceridemia, hypercholesterolemia, arterial hypertension, and cardiovascular prevention treatment at baseline. The presence of both conditions was associated with a higher risk of developing albuminuria compared to having steatotic liver disease alone (HR 5.91; 95% CI 1.15–30.41, p = 0.033). Compared with the first tertile of visceral adipose tissue, the proportion of subjects with liver steatosis and abnormal epicardial adipose tissue was significantly higher in the second and third tertile. We found a significant correlation between epicardial fat and steatotic liver disease (rho = 0.43 [p
- Published
- 2024
- Full Text
- View/download PDF
50. Long-term comparison of renal and metabolic outcomes after sodium–glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes
- Author
-
Minji Sohn, Seoungyeon Nam, Michael A. Nauck, and Soo Lim
- Subjects
SGLT2 inhibitor ,GLP1 receptor agonist ,Renal outcome ,eGFR ,Albuminuria ,Medicine - Abstract
Abstract Background Renal outcomes in patients with type 2 diabetes following treatment with sodium–glucose co-transporter-2 inhibitors (SGLT2is) or glucagon-like peptide-1 receptor agonists (GLP1RAs) have not been directly compared. This study compared the impact of SGLT2i and GLP1RA therapy on renal function and metabolic parameters. Methods Patients with type 2 diabetes who initiated SGLT2i or GLP1RA therapy in a tertiary hospital between January 2009 and August 2023 were included to assess composite renal outcomes, such as a 40% decline in estimated glomerular filtration rate (eGFR), onset of end-stage renal disease, renal death, or new-onset macroalbuminuria. Alterations in blood pressure, glucose regulation parameters, lipid profile, and anthropometric parameters, including body fat and muscle masses, were examined over 4-years. Results A total of 2,112 patients were enrolled using a one-to-three propensity-score matching approach (528 patients for GLP1RAs, 1,584 patients for SGLT2i). SGLT2i treatment was favoured over GLP1RA treatment, though not significantly, for composite renal outcomes (hazard ratio [HR], 0.63; p = 0.097). SGLT2i therapy preserved renal function effectively than GLP1RAs (decrease in eGFR, ≥ 40%; HR, 0.46; p = 0.023), with improving albuminuria regression (HR, 1.72; p = 0.036). SGLT2i therapy decreased blood pressure and body weight to a greater extent. However, more patients attained HbA1c levels
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.